{"id":"W2886734654","doi":"10.1158/1538-7445.am2018-ct053","title":"Abstract CT053: Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced NSCLC and MSI-H endometrial cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pharmacokinetics; Lung cancer; Monoclonal antibody; Clinical trial; Antibody; non-small cell lung cancer (NSCLC); Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001665953,0.001167647,0.001156472,0.0005060488,0.0005024914,0.0009709505,0.0008959651,0.0007816007,0.004740626],"category_scores_gemma":[0.001173599,0.0004429878,0.0007958319,0.0006475075,0.0008478254,0.0006222151,0.0003286848,0.002260843,0.0009665678],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001388769,"about_ca_system_score_gemma":0.002073066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001986119,"about_ca_topic_score_gemma":0.00401944,"domain_scores_codex":[0.9993523,0.0003152583,0.00004620153,0.00009690007,0.0001069365,0.00008239809],"domain_scores_gemma":[0.9992813,0.0001428719,0.0001329166,0.00009124296,0.00006316286,0.0002884328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3916782,0.0358534,0.03670928,0.001072778,0.0009342637,0.001154733,0.0005708458,0.006502062,0.3751654,0.0005259134,0.01060795,0.1392253],"study_design_scores_gemma":[0.1505851,0.5740217,0.1378889,0.00007308491,0.001195233,0.00360414,0.0001665615,0.005549719,0.1107328,0.000450253,0.01560129,0.0001312934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898811,0.001395555,0.001050702,0.0002268519,0.0000258087,0.001265918,0.003571087,0.0001382277,0.00244471],"genre_scores_gemma":[0.980346,0.0006205331,0.002427042,0.0004697849,0.00005268684,0.001178658,0.01246485,0.00005450839,0.002385818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004740626,"threshold_uncertainty_score":0.01585895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05732046664254814,"score_gpt":0.4303570550663582,"score_spread":0.37303658842381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}